
EIDX
Healthcare · Biotechnology · $4.75B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2020
EPS trend, 90 days to now · +1.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2020 | After the close | -0.71 | -0.79 | -11.6% |
| Aug 6, 2020 | After the close | -0.56 | -0.75 | -35.1% |
| May 8, 2020 | After the close | -0.53 | -0.60 | -13.7% |
| Feb 26, 2020 | After the close | -0.48 | -0.51 | -6.4% |
| Oct 31, 2019 | After the close | -0.27 | 0.18 | +166.5% |
| Aug 1, 2019 | After the close | -0.37 | -0.39 | -4.8% |
| Apr 15, 2019 | After the close | -0.28 | -0.27 | +4.4% |
| Feb 27, 2019 | Time not confirmed | -0.25 | -0.27 | -9.1% |
| Nov 6, 2018 | After the close | -0.27 | -0.29 | -6.1% |
| Aug 7, 2018 | After the close | -0.23 | -0.29 | -26.9% |
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in…